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Objectives: To evaluate the clinical and microbiological appearance among hospitalized
pneumonia patients focusing on resistance and risk factors for mortality in a referral hospital.
Patients and methods: The study was an observational retrospective study on patients
with CAP from 2014 to 2016 at Dr Soetomo referral hospital of Surabaya, Indonesia. All
positive cultures with antimicrobial susceptibility results from blood and respiratory speci-
mens were included. Patients infected with drug-susceptible pathogens and MDR organisms
were also assessed in terms of clinical characteristics, day-3 clinical improvement, and 14-
day mortality.
Results: Of 202 isolates, 181 possessed antimicrobial susceptibility data. S. pneumoniae was
the most prevalent pathogen causing CAP (18.3%). Most patients were empirically treated
with ceftriaxone (n=75; 41.4%). Among beta-lactam antibiotics, the susceptibility to the
third-generation cephalosporins remained relatively high, between 67.4% and 82.3%, com-
pared with the other beta-lactams such as amoxicillin/clavulanate and ampicillin/sulbactam
(a sensitivity rate of 36.5% and 47.5, respectively). For carbapenem antibiotics, imipenem
and meropenem susceptibility was 69.6% and 82.3% respectively. Approximately 22% of
isolates were identiﬁed as MDR that showed signiﬁcant differences in clinical outcomes of
14-day mortality rates (p<0.001). Notably, patients with day-3 improvement had a lower risk
of mortality (OR= 0.06; 95% CI= 0.02–0.19).
Conclusion: One-ﬁfth of causative agents among hospitalized CAP cases were identiﬁed as
MDR organisms. The pathogens of MDR and non-MDR CAP remain susceptible to the
third-generation cephalosporins. Together with additional consideration of culture ﬁndings
and Pneumonia Severity Index (PSI) assessment, a 3-day clinical assessment is essential to
predict the prognosis of 14-day mortality.
Keywords: gram-negative bacteria, pneumonia, microbial sensitivity tests, developing
country, day-3 improvement
Introduction
Community-acquired pneumonia (CAP) is mostly due to bacterial infections
which are speciﬁcally recognized as community-acquired bacterial pneumonia
(CABP).1 All guidelines agree that at least one empiric antibiotic is
needed especially for hospitalized patients.2–5 The international association,
Community-Acquired Pneumonia Organization (CAPO) reported that between
2001 and 2011 mortality rates of the infection reached 7.3%, 9.1%, and 13.3%,
in North America, Europe, and South America respectively.6 In 2013, the
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incidence rates of CAP in low-middle-income countries
(LMICs) such as Indonesia was 4.5% and remained high
at 4% in 2018.7,8 No available published data relates to
the mortality of the disease in the country.
In order to achieve the appropriate therapeutics,
updated epidemiology of antimicrobial resistance is
required to support therapeutic guidelines. International
associations such as the British and American Thoracic
Societies (BTS and ATS) have indicated that gram-posi-
tive bacteria are the most widespread causes of CAP.3,5
Nevertheless, the guidelines reﬂected studies published in
2003 from high-income countries where Streptococcus
pneumoniae was identiﬁed as the dominant pathogen caus-
ing CAP,9 and beta-lactam antibiotics were recommended
as the preferred treatment.2,3,5
Studying CAP among LMICs, etiology of the disease
was generally problematic. Less restriction of antibiotic
use in the community and the differences in the healthcare
systems in LMICs may impact on the existence of MDR
pathogens.10,11 Indiscriminate use of antimicrobials, not
guided by microbiological guidance, generally results in
the emergence of antimicrobial resistance, both for indivi-
dual patients and at the community level. The World
Health Organization (WHO) has labeled the use of anti-
infectives with a high warning in the global report on
surveillance of antimicrobial resistance.12 Antibiotic resis-
tance leads to long hospitalization periods, treatment fail-
ure, and a high economic burden.13,14
Local epidemiology may vary by country, and there-
fore local protocols and guidelines should be based on
local prevalence and susceptibility data, which will guide
appropriate use of antibiotics, thereby improving out-
comes, reducing the duration of hospitalization and pre-
venting the emergence of antimicrobial resistance with
inherent increased costs. The local epidemiology of CAP
etiology could support stakeholders to develop strategies
on prescribing to control the resistance in the community
and in hospitals. The major gap between the guidelines’
review and the local patterns in terms of the pathogens
causing CAP may drive several healthcare centers to
implement the use of different antibiotics as alternative
treatments to the resistance of community infections.15
Notably, Acinetobacter baumannii infections associated
with CAP contributed to multidrug resistance (MDR) and
has led to high mortality in Asia Paciﬁc countries.16–18 In
Indonesia, the data on recent CAP etiology and MDR is
limited. This study aims to analyze on the etiology of CAP
and MDR-CAP, with a focus on the rate of antibiotic
resistance and the risk factors for CAP-related mortality
in an Indonesian tertiary referral hospital.
Materials And Methods
Study Design And Ethical Approval
We performed a retrospective observational study invol-
ving adult patients newly admitted to hospital with CAP.
We collected the data from Dr. Soetomo Hospital, a large
tertiary referral and academic hospital with approximately
1,514 beds in East Java, Indonesia. The study proposal
was submitted to the research and development center of
Dr. Soetomo Hospital. The study was approved by the
ethical committee of Dr. Soetomo Hospital, Surabaya,
Indonesia, with letter no. 480/Panke.KKE/X/2014). The
committee decided that the study did not need a review
in terms of patient consent because of the retrospective
observational design. The study complies with the agree-
ment on Indonesia research conduct and the Declaration of
Helsinki (Ethical Principles for Medical Research
Involving Human Subjects version 2013).19 The data was
obtained from the medical record department with patient
anonymity and conﬁdentiality maintained.
Patients And Treatment
The data was gathered from the inpatient registry database
with an International Classiﬁcation of Diseases (ICD) code
of 10 J.18.x from 2014 to 2016. The inclusion criteria of the
study included all inpatients aged 20 years or above with
CAP as a primary diagnosis. The respiratory tract sputum or
blood samples were collected before the start of empirical
antimicrobial treatment. We only included patients who met
the diagnosis based on the national guidelines for CAP from
the Indonesian Society of Respirology.20 The diagnosis was
based on new pulmonary inﬁltrates on the chest radiograph,
progressive cough, purulent sputum, fever (>38°C), and at
least two additional symptoms consisting of increased dys-
pnea, pleuritic pain, leukocytosis (>10,000/mm3) or leuko-
penia (<4,500/mm3), lung consolidation suggested by
dullness to percussion of the chest, and abnormal chest
auscultation ﬁndings including crepitations, crackles, or
rhonchi. We excluded patients who had received parenteral
antibiotics 48 hrs before hospitalization, those with negative
cultures, and those hospitalized in other healthcare facilities
more than 14 days within 30 days before the current hospi-
tal admission. Regarding CAP diagnosis, a pulmonologist
made a visit at the ﬁrst 24–48 hrs of admission to clarify the
diagnosis. Therefore, we also excluded patients who died
Purba et al Dovepress
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within 24 hrs after admission. In the hospital, patients
received empirical antibiotics according to a guideline of
the Indonesian Society of Respirology for CAP within 24h
of admission. To ensure adequate identiﬁcation of etiology
among CAP patients who had culture samples obtained
after empirical antibiotic administrations, and also excluded
any patients whose culture samples were obtained more
than 48 hrs after admission. The description of the manage-
ment of hospitalized CAP patients is presented in Table 1.
Microbiological Evaluation
Bacterial culture from patients’ sputum and blood samples
collected within the ﬁrst 24h of admission was tested for
microbiological evaluation. In terms of quality, the sputum
was considered to be acceptable where it contained >25 gran-
ulocytes and <10 squamous epithelial cells per low-powerﬁeld
(x10).21 The eligible sputum specimen was subsequently sub-
mitted to species identiﬁcation and susceptibility testing. We
assessed the susceptibility to the available antimicrobial agents
in the hospital including amoxicillin-clavulanate (AMC),
ampicillin-sulbactam (SAM), ticarcillin-clavulanate (TIC),
piperacillin-tazobactam (PIP), cefazolin (CFZ), ceftazidime
(CAZ), cefoperazone-sulbactam (CFP, trimethoprim-sulfa-
methoxazole (STX), ciproﬂoxacin (CIP), levoﬂoxacin
(LVX), moxiﬂoxacin (MXF), imipenem (IPM), and merope-
nem (MEM). Testing of amikacin (AMK) and gentamicin
(GEN) susceptibilitieswere conducted only forGram-negative
bacteria (GNB). In particular, vancomycin susceptibility was
tested on Gram-positive bacteria (GPB) only. Pathogens were
deﬁned as multidrug-resistant (MDR) if the organisms were
resistant to at least one single agent in three or more groups of
antimicrobial agents.22 The antimicrobial susceptibility pattern
was reported as sensitive (S), intermediate-susceptible (I), or
resistant (R) for each isolated species based on the microbiol-
ogy department of the hospital using the Clinical and
Laboratory Standards Institute (CLSI) criteria.23
Clinical Evaluation
To explore the impact of MDR infections compared to non-
MDR infections, we compared baseline demographics, physi-
cal examination, laboratory and radiology ﬁndings, comorbid-
ities, pneumonia severity index (PSI) scores, the need for
intensive care, the empirical antimicrobial treatment given,
length of stay (LoS), clinical improvement on day-3, and 14-
daymortality. On day-3 of hospital admission, we assessed the
following clinical symptoms comparing with baseline on
admission: mental status; respiratory rate (n: 12–24/min);
heart rate (n:≤100 beats/min); systolic blood pressure (cut-off
≥90 mmHg); arterial oxygen saturation (cut-off: ≥90%); oral
intake ability; temperature (<38.5°C); and leucocyte count
(3.5–10.5 x109/L).3 PSI is a validated scoring system repre-
senting the baseline physiologic parameters and pre-existing
comorbidities adding up a total score of 19 factors; the total
score is categorized into ﬁve classes: class I (<51), class II (51–
70), class III (71–90), class IV (91–130), and class V (>130).24
Statistical Analysis
The statistical analyses were performed using SPSS (SPSS 23,
University of Groningen, Netherlands). For categorical data,
chi-square (or Fisher exact test with more than 20% cells with
Table 1 Indonesian Guideline For CAP Patients
Patient Care The Strategies:
Wards One of the following options:
1. Beta-lactam iv + beta-lactamase inhibitor iv
2. The second and third generation of cephalosporins iv
3. Respiratory ﬂuoroquinolone iv
Macrolide (additional antibiotic when atypical infections identiﬁed)
Intensive care No pseudomonal infection:
1. The third-generation of cephalosporin iv + macrolide
When a pseudomonal infection presents, one of the following options:
1. Anti-pseudomonal cephalosporin iv
2. Carbapenem iv + anti-pseudomonal antibiotic iv
3. Aminoglycoside iv
If there is an atypical infection, using the following three-drug combination:
Anti-pseudomonal cephalosporin iv (or carbapenem iv) + macrolide (or respiratory ﬂuoroquinolone iv) + aminoglycoside iv
Note: Adapted from Indonesian Society of Respirology. Guideline for diagnosis and management of community pneumonia in Indonesia[Perhimpunan Dokter Paru Indonesia.
Pneumonia komuniti: pedoman diagnosis & penatalaksanaan di Indonesia]. 2003. Available: http://www.klikpdpi.com/konsensus/konsensus-pneumoniakom/pnkomuniti.pdf.20
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expected values less than 5) were used. For continuous vari-
ables, the distribution of data was ﬁrst tested. Datawith normal
distribution were provided as mean and standard deviation
(SD). Otherwise, the data were expressed as median with
25th and 75th percentiles. The differences among the empiri-
cal antibiotics on all analyses were considered statistically
signiﬁcant at p-value <0.05. Multivariate analysis was used
to determine whether there was an independent association of
three risk factors of 14-day mortality. First, the host factors
analyzed were gender, age (60 or above), cardiovascular dis-
ease, neoplasm, diabetes mellitus (DM), liver diseases, renal
insufﬁciency, since those comorbidities were independent risk
factors of mortality.25,26 Also, PSI class 3 or above, and day-3
improvement were integrated assessments considered in the
analyses. Second, the pathogen factor of drug-susceptible or
MDR. Third, the treatment: combinations of empirical anti-
microbials compared to a single antimicrobial agent. Each risk
factor was presented as an odds ratio (OR) with a conﬁdence
interval (CI) of 95% where the value of 95% CI not including




Two hundred and two bacterial isolates were collected from
181 patients. Each patient had one result of antimicrobial
susceptibility testing. The identiﬁed causative agents are
shown in Table 2. Most culture specimens were collected
Table 2 Etiology Characteristics (n=202 Isolates)
Bacterial Agents N Percentage Blood Culture Sputum Culture MDR-CAP
Single-agent
A. baumannii 27 13.4 27 13
Enterobacter spp 10 5.0 10 3
E. coli 10 5.0 10 1
K. pneumoniae 25 12.4 25 9
P. aeruginosa 18 8.9 18 8
S. aureus 9 4.5 9 2
S. non-haemolyticus 4 2.0 4
S. pneumoniae 26 12.9 26 1
S. viridans 31 15.3 31
Mixed-agents
A. baumannii 1 0.5 1
+ M. tuberculosis 1 0.5 1
Enterobacter spp 1 0.5 1 1
+ H. inﬂuenzae 1 0.5 1
K. pneumoniae 1 0.5 1 1
+ M. tuberculosis 1 0.5 1
K. pneumoniae 1 0.5 1 1
+ H. inﬂuenzae 1 0.5 1
P. aeruginosa 1 0.5 1 1
+ Pantoe agglomerans 1 0.5 1
S. pneumoniae 1 0.5 1
+ Cronobacter sakazakii 1 0.5 1
S. pneumoniae 4 2.0 4
+ H. inﬂuenzae 4 2.0 4
S. pneumoniae 4 2.0 4 1
+ M. tuberculosis 4 2.0 4
S. pneumoniae 2 1.0 2
+ Staphyloccus spp (coagulase negative) 2 1.0 2
S. viridans 2 1.0 2 1
+ M. tuberculosis 2 1.0 2
S. viridans 3 1.5 3 1
+ H. inﬂuenzae 3 1.5 3
Purba et al Dovepress
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from the respiratory tract (97.5%). The dominant pathogen
was S. pneumoniae (18.3%) followed by S. viridans (17.8%),
A. baumannii (13.9%), K. pneumoniae (13.4%), P. aerugi-
nosa (9.4%), Enterobacter spp. (5.4%), E. coli (5%),
S. aureus (4.5%). Isolates of H. inﬂuenzae (4.5%),M. tuber-
culosis (4%), S. non-haemolyticus (2%), and Coagulase-
Negative Staphylococci (1%) were identiﬁed as mixed
pathogens. Of all identiﬁed bacteria, 44 were MDR organ-
isms (22%), of which A. baumannii demonstrated to be the
most prevalent pathogen among MDR isolates (6.4%)
(Table 2). Ciproﬂoxacin and amoxicillin/clavulanic had the
lowest potential efﬁcacy of antibiotics against MDR organ-
isms (Figure 1). In general, with reference to all pathogens
(n=181), the third-generation cephalosporins had fair sensi-
tivity at 67.4%, 70.2%, 70.7%, and 82.3% for cefotaxime,
ceftriaxone, ceftazidime, cefoperazone respectively.
Vancomycin appeared susceptible to all GPB. Likewise,
among GNB, susceptibility was 84.2% for amikacin and
78.9% for gentamicin (Table 3).
The Impact Of MDR Infections On
Clinical Manifestation
A total of 181 patients satisﬁed the study criteria. Patients
were predominantly male (64.6%) with a mean age of 56.5
years. Predominant complaints during hospital admission
were dyspnea (98.3%) and fever (96.1%). Another com-
mon clinical presentation was cough and chest discomfort,
documented at 73.5% and 21%, respectively. The most
common comorbidity was diabetes mellitus (28.2%) fol-
lowed by neoplasm (25.4%), cardiovascular disease
(11.6%), renal insufﬁciency (17.1%) and hepatic disorder
(7.2%) (Table 4).
Within non-MDR infections, most patients clinically
manifested with PSI class III (49.6%). In contrast, patients
with MDR infections were mostly in PSI class IV (43.2%).
Of 44 patients with MDR, 22.7% needed intensive care,
which was a signiﬁcantly higher proportion than those
with non-MDR (13.1%). Also, the most common antibio-
tics for empirical treatment either as single or combined
use were ceftriaxone (49.2%), ceftazidime (39.8%), and
levoﬂoxacin (27.6%). The use of empirical antibiotic com-
bination was higher in patients with MDR (34.1%) com-
pared to non-MDR infections (10.9%).
Bivariate comparisons of patient characteristics and the
clinical outcomes between non-MDR and MDR infections
are presented in Table 4. The clinical characteristics and
clinical outcomes were signiﬁcantly different with respect
to neoplasm (17.5% vs 50%), DM (24.1% vs 40.9%), PSI
class I to V (p-value=0.003), day-3 improvement (55.5%
vs 11.4%) and 14-day mortality (21.9% vs 26.8%). The
median duration of hospitalization between the two groups
was not signiﬁcantly different (11.5 vs 12.6 d).
The Risk Factors Of Mortality
Multivariate analysis of variables considered relevant to
the outcome of 14-day mortality is presented in Table 5.
Among patient factors, patients with neoplasm (OR=2.76;
Figure 1 Resistance, intermediate, and sensitivity rates of multidrug-resistant agents causing hospitalized community-acquired pneumonia.
Dovepress Purba et al
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95% CI=1.03–7.36) and those with PSI class III or above
(OR=9.19; 95% CI=1.51–55.89) had a signiﬁcantly
increased risk of mortality. Clinical improvement at day-
3 appeared to provide protection, with decreased mortality;
OR=0.06; 95% CI=0.02–0.19.
Discussion
Our study suggests that CAP in the study area is not only
caused by GPB but also frequently by GNB. The patho-
gens generally remained sensitive to third-generation
cephalosporins which are also recommended by the local
guideline. Microbiological culturing of sputum and blood
provided clinically relevant information concerning the
identity of pathogens with their susceptibility to antimi-
crobials. Clearly amoxicillin and penicillin even if com-
bined with a beta-lactamase inhibitor are no longer
effective in our setting. Our results support a strategy to
avoid these agents for patients admitted to hospital with
CAP, particularly in LMICs. Empirical treatment for CAP
should indeed be guided by culture data that are locally
obtained and susceptibility testing.27,28
In our study, S. pneumoniae was the most common
pathogen, with conserved penicillin susceptibility. A
study on S. pneumoniae infections in 13 Asian countries
reported that the incidence of the pathogen was high at
29.2% among CAP in Pan-Asia.29 Mixed pathogens are an
important consideration since they may lead to delayed
response or even a lack of clinical improvement. Like the
systematic review conducted on studies in Asia, our ﬁnd-
ings also revealed mixed infections with S. pneumoniae
and M. tuberculosis or H. inﬂuenzae.30,31 In contrast to
community-acquired viridans streptococcal pneumonia,
our study pointed out that the organism had low sensitivity
to amoxicillin/clavulanate acid. The mechanism of resis-
tance to penicillin among S. viridans isolates seems to be
through alteration of the penicillin-binding proteins
(PBPs), especially among patients with underlying
diseases.32 The change on the site of PBPs generates
inadequate binding not only for penicillin but also for
other β-lactams including cephalosporins.33,34 S. viridans
organisms in our study might also represent normal micro-
bial ﬂora as colonization in the upper-respiratory tract.35,36
However, invading to lower-respiratory tract or blood-
stream, S. viridans could lead to serious infections. In
previous clinical reports, S. viridans could cause compli-
cations of parapneumonic effusion or empyema in patients
with CAP.37–39 One of the important organisms commonly
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Table 4 Comparisons Of Clinical Characteristics Between Non-MDR and MDR
Clinical Characteristics All Patients (n=181) Non-MDR (n=137) MDR (n=44) p-Value
Gender
Male, n (%) 117(64.6) 84(61.3) 33(75.0) 0.099
Female, n (%) 64(35.4) 53(38.7) 11(25.0)
Age (years), mean (SD) 56.5(12.8) 55.7(12.6) 59.0(13.5) 0.157
Chief complaints at hospital admission
Fever, n (%) 174(96.1) 130(94.9) 44(100.0) 0.137
Cough, n (%) 133(73.5) 100(75.2) 33(24.8) 0.793
Dyspnea, n (%) 178(98.3) 134(97.8) 44(100.0) 0.431
Chest discomfort, n (%) 38(21.0) 26(19.0) 12(27.3) 0.240
RR (/min), median (P25-P75) 26(22–28) 24(22–28) 26(22.5–28) 0.210
Body temperature (°C), median (P25-P75) 37.0(36.7–37.8) 37.0(36.7–37.8) 37.0(36.7–37.7) 0.756
Blood leucocytes (per mm3), median (P25-P75) 14,865(11,450–18,650) 15,000(11,500–18,200) 14,075(11,155–19,700) 0.750
SBP (mmHg), median (P25-P75) 120(110–130) 110(110–130) 120(110–140) 0.253
DBP (mmHg), median (P25-P75) 70(70–80) 70(70–80) 75(70–80) 0.929
Arterial blood gas
pH, median (P25-P75) 7.44(7.40–7.49) 7.44(7.40–7.49) 7.43(7.39–7.50) 0.721
pCO2 (mmHg), median (P25-P75) 36.0(31.0–45.7) 37.0(31.0–47.0) 35.0(30.6–39.6) 0.149
pO2 (mmHg), median (P25-P75) 76.1(67.0–98.4) 78.0(68.0–101.5) 76.0(61.0–95.7) 0.152
Base excess, median (P25-P75) 1.1(−2.0–5.8) 1.8(−1.8 to 6.0) 0.3(−3.3 to 4.5) 0.192
HCO3, median (P25-P75) 25.2(22.2–30.3) 25.7(22.4–30.5) 24.9(21.7–28.6) 0.292
SO2, median (P25-P75) 96.0(94.0–98.1) 96.0(94.0–98.1) 96.3(92.2–98.3) 0.509
Pleural effusion, n (%) 26(14.4) 19(13.9) 7(15.9) 0.737
Co-morbidities
Cardiovascular diseases, n (%) 21(11.6) 15(10.9) 6(13.6) 0.628
Neoplasm, n (%) 46(25.4) 24(17.5) 22(50.0) <0.001*
Diabetes mellitus, n (%) 51(28.2) 33(24.1) 18(40.9) 0.031*
Hepatic disorder, n (%) 13(7.2) 9(6.6) 4(9.1) 0.392
Renal insufﬁciency, n (%) 31(17.1) 22(16.1) 9(20.5) 0.501
PSI class
Class I, n (%) 14(7.7) 13(9.5) 1(2.3) 0.003*
Class II, n (%) 22(12.2) 20(14.6) 2(4.5)
Class III, n (%) 84(46.4) 68(49.6) 16(36.4)
Class IV, n (%) 48(26.5) 29(21.2) 19(43.2)
Class V, n (%) 13(7.2) 7(5.1) 6(13.6)
Intensive care 28(15.5) 18(64.3) 10(22.7) 0.126
Empirical antibiotics
Ceftazidime, n (%) 56(30.9) 44(32.1) 12(27.3) 0.506
Ceftriaxone, n (%) 75(41.4) 63(46.0) 12(27.3)
Levoﬂoxacin, n (%) 20(11.0) 15(10.9) 5(11.4)
Ceftazidime + levoﬂoxacin, n (%) 16(8.8) 9(6.6) 7(15.9)
Ceftriaxone + levoﬂoxacin, n (%) 14(7.7) 6(4.4) 8(18.2)
Clinical follow-up
Length of stay, median (P25-P75) 12.0(8.0–16.0) 11.5(8.0–15.8) 12.6(9.0–16.4) 0.374
Day-3 improvement, n (%) 81(44.8) 76(55.5) 5(11.4) <0.001*
14-day mortality rates, n (%) 55(30.4) 30(21.9) 25(56.8) <0.001*
Note: *Statistically signiﬁcant, p-value < 0.05.
Abbreviations: DBP, diastolic blood pressure; max, maximum; med, median; min, minimum; MDR, multidrug-resistant; PSI, pneumonia severity index; RR, respiratory rate;
SBP, systolic blood pressure.
Purba et al Dovepress
submit your manuscript | www.dovepress.com
DovePress































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Methicillin-resistant Staphylococcus aureus (MRSA).40
Community-acquired MRSA (CA-MRSA) has emerged
as an important pathogen for CAP. In several hospitals in
Indonesia, an identiﬁcation test of MRSA for pneumonia
patients has not been routinely conducted considering the
cost and the results of a previous study reporting the low
prevalence of CA-MRSA among patients admitted to the
hospital.41
We identiﬁed A. baumannii as a causative agent for CAP
with high antimicrobial resistance. GNB has been deter-
mined as the dominant pathogen causing CAP in Indonesia
and other countries of Asia.30,31,42 Outbreaks of A. bauman-
nii are currently responsible for community and nosocomial-
infectious diseases such as in South Asia where the species
has been observed as a cause of pneumonia since 1989.43
Acinetobacter species are commonly encountered as coloniz-
ing organisms in the upper-respiratory and gastrointestinal
tracts.44 Therefore,MDR Acinetobacter is problematic, espe-
cially in immunocompromised hosts. Of 28 Acinetobacter
infections in our study, around 60% were highly resistant to
ciproﬂoxacin. Similarly, the results from a previous study
investigated the resistance mechanism of 75 Acinetobacter
species fromWalter Reed ArmyMedical Center (WRAMC).
Among the respiratory specimens, 80% of isolates were
identiﬁed as being resistant to ciproﬂoxacin and cefepime.45
In addition, we found that E. coli had poor sensitivity to
penicillins. Most of the isolates were highly sensitive to
third-generation cephalosporins, ﬂuoroquinolones, and
carbapenems. A previous study in Indonesia found that 8%
of E. coli were resistant to ciproﬂoxacin commonly through
independent selection among resistant mutants.46 Notably,K.
pneumoniae presented as the highest prevalent GNB in 7
Asian countries with a low resistance rate to cefuroxime and
ceftriaxone.47 K. pneumoniae in Indonesia should be consid-
ered as a threat for potential outbreaks as 15% of adults, and
7% of children tested carried this organism.48 Previous evi-
dence regarding CAP etiology in Semarang, the sixth biggest
city in Indonesia, has reported results in line with this study.
The study found that the prevalence of K. pneumoniawas the
most commonly identiﬁed among bacteria causing CAP.
MDR K. pneumoniae, E. coli, and Enterobacter spp.
expressed extended-spectrum b-lactamases (ESBLs). These
enzymes inactivate penicillins and cephalosporins leading to
limited treatment options with currently available antimicro-
bial agents.24
The clinical relevance of GNB ﬁndings from respira-
tory specimens among pneumonia patients is usually
debated as it might reﬂect colonization rather than pul-
monary infection. Low awareness of infection prevention
and high transmission between patients and the commu-
nity is challenging in LMICs. The prevalence of GNB is
lower in some regions especially in Europe, the US, and
Canada except in the context of hospital-acquired
pneumonia;49–51 notably different from reports from
Asian countries, as reﬂected by recommendations made
by the ATS and BTS in their respective guidelines.3,5,47
Table 5 Multivariate Analysis Of Risk Factors For Mortality Among CAP Patients
Variable CAP Mortality Univariate Analysis Multivariate Analysis
No (n=126) Yes (n=55) OR 95% CI p-value aOR 95% CI p-value
Host factors
Male 82(65.1) 35(63.6) 0.939 0.485–1.817 0.852 0.483 0.190–1.229 0.127
Age>60 40(31.7) 26(47.3) 1.928 1.008–3.688 0.047 1.482 0.585–3.751 0.407
Cardiovascular disease 9(7.1) 12(21.8) 3.628 1.428–9.216 0.007 2.401 0.684–8.422 0.171
Neoplasm 21(16.7) 25(45.5) 4.167 2.053–8.458 <0.001 2.755* 1.031–7.361 0.043
Diabetes mellitus 24(19.0) 27(49.1) 4.098 2.054–8.177 <0.001 2.098 0.780–5.642 0.142
Liver disease 7(5.6) 6(10.9) 2.082 0.666–6.509 0.208 3.800 0.633–22.810 0.144
Renal insufﬁciency 18(14.3) 13(23.6) 1.857 0.837–4.123 0.128 1.917 0.592–6.201 0.277
PSI class ≥3 92(73.0) 53(96.4) 9.793 2.262–42.407 0.002 9.188* 1.510–55.891 0.016
Day-3 improvement 77(61.1) 4(7.3) 0.050 0.017–0.147 <0.001 0.055* 0.016–0.190 <0.001
Agent factor
MDR-bacterial infections 19(15.1) 25(45.5) 4.693 2.282–9.651 <0.001 1.259 0.471–3.361 0.646
Treatment factor
Antibiotic combination 14(11.1) 16(29.1) 3.282 1.468–7.338 0.004 2.424 0.717–8.196 0.154
Note: *Statistically signiﬁcant in multivariate analysis, the aOR CI95% does not include a value of 1.
Abbreviations: CAP, community-acquired pneumonia; MDR, multidrug resistance; OR, odds ratio; aOR, adjusted odds ratio; PSI, pneumonia severity index.
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The crucial concern of CAP management in most
guidelines is P. aeruginosa infection, which carries a
poor prognosis and high mortality.2,3,5,20 In our study,
P. aeruginosa remained sensitive to anti-pseudomonal
β-lactam antibiotics such as ceftazidime and cefoperazone.
Comparing our results with other LMICs, our ﬁndings
were similar to a Nigerian study on 232 pneumonia
patients with 77% and 75.5% having isolates sensitive to
ceftazidime and levoﬂoxacin, respectively.52 For Egypt, a
study on CAP revealed that P. aeruginosa had the highest
resistance to levoﬂoxacin (56.5%) followed by ciproﬂox-
acin and piperacillin/tazobactam which rated at 47.8%.53
Malignancy as an underlying disease was earlier
reported to be associated with high mortality (27%)
among CAP patients.54 Neoplastic disease is scored +30
in the PSI scoring system.24 A prediction value of PSI has
been used widely to estimate mortality. PSI class III or
above indicates that the risk of death is high, and the
patients need hospitalization. We used PSI categorization
since this system includes 19 comprehensive aspects.
According to ATS/IDSA guidelines, patients started on
empirical antimicrobial therapy who show clinical
improvement within the ﬁrst three days could safely be
switched from intravenous to oral antibiotics.3,55 In our
study, we explored whether the day-3 evaluation would be
a critical time point to evaluate the efﬁcacy of empirical
treatment and to estimate patients’ risk of mortality. An
assessment of clinical response at day 4 of patients with
community-acquired bacterial pneumonia (CABP) was
also suggested by the Food and Drug Administration
(FDA) guidance.56 In line, our ﬁndings recommend a
combination assessment of clinical response in the ﬁrst
three days as an additional value to PSI scoring where
both assessments were investigated as independent risk
factors for mortality among patients with pneumonia.
Moreover, the successful treatment response to empirical
treatment could help to switch to oral antimicrobial treat-
ment on day 3, with additional information that will then
be available from culture and susceptibility data from the
Microbiology Laboratory.
Despite the results obtained in the study, there were
several limitations. First, only patients with a positive cul-
ture were included. Thus the results may not be representa-
tive for all patients especially those in whom culturing was
either not tried, or failed to yield causative organisms.
Second, we did not include antibiotics given after culture
results became available especially in critically ill patients
where the selection of antimicrobial drugs and the dosages
may have impacted on the clinical outcomes, including
mortality. Third, we conducted the study at a single center,
albeit a large hospital in Indonesia; extrapolation of our
results needs conﬁrmation in other centers on Java or even
Indonesia and beyond. Forth, our exclusion of patients who
died within 24 hrs might have caused bias, with the most
severely ill patients potentially having an early fatal out-
come. Notwithstanding, in the absence of a speciﬁed and
veriﬁed diagnosis, valid inclusion seemed impossible. A
further limitation of our study concerns the fact that it is
not impossible that some CAP diagnoses were misclassiﬁed
hospital-/ventilator-acquired pneumonia. Given the involve-
ment of the pulmonologist in specifying and verifying the
diagnosis in an early stage, we do not expect many (or even
any) misclassiﬁcations in this respect.
However, the study provides updated information
about the local pattern of resistance to antimicrobials
among MDR-CAP. The presence of MDR organisms in
the community is an indicator of the complex hindrances
faced in the implementation of the national health system.
Besides high transmission of pathogens in the tropical
environment, the free access to antibiotics in the commu-
nity among LMICs could be the main cause of MDR.
The study supports the notion that the use of antibiotics
in the community urgently needs to be restricted to control
the emergence of further resistance. Private sectors and
governments need to monitor the pattern of pathogens and
the resistance to antibiotics regularly. Our report adds
important information needed to select empirical antimi-
crobial treatment for CAP, including the coverage of GNB
infections for LMICs like Indonesia.
Conclusion
S. pneumoniae was the predominant pathogen of hospita-
lized CAP. GNB were common as well, and these organ-
isms should likewise be considered and covered in
empirical treatment. A. baumannii and K. pneumoniae
were common and carried a high risk for MDR-CAP.
Concerning the implementation of the local guideline
where β-lactam antibiotics are used for empirical treatments
in CAP patients, the pathogens generally remain highly
susceptible to the third-generation cephalosporins. Rapid
and advanced microbiological diagnostics are required to
monitor further drug resistance emergence and to ensure
that empirical therapy remains effective for CAP. This data
should be incorporated in the design for local guidelines for
empirical treatment of CAP. Eventually, we recommend
assessing clinical response to therapy within the ﬁrst three
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days follow up as this has an important prognostic value
that adds to the PSI scoring system and microbiological
evaluation.
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